SGMO Sangamo Therapeutics, Inc. Stock Quote

SGMO [NASD]

Index	-	P/E	-	EPS (ttm)	-0.93	Insider Own	0.80%	Shs Outstand	141.56M	Perf Week	0.68%
Market Cap	1.75B	Forward P/E	-	EPS next Y	-1.26	Insider Trans	-2.75%	Shs Float	116.56M	Perf Month	-5.88%
Income	-121.00M	PEG	-	EPS next Q	-0.30	Inst Own	55.40%	Short Float	14.17%	Perf Quarter	-18.22%
Sales	118.20M	P/S	14.77	EPS this Y	-6.00%	Inst Trans	-3.65%	Short Ratio	11.26	Perf Half Y	11.79%
Book/sh	3.52	P/B	3.37	EPS next Y	-0.80%	ROA	-14.30%	Target Price	19.80	Perf Year	45.40%
Cash/sh	4.35	P/C	2.72	EPS next 5Y	-	ROE	-25.10%	52W Range	7.65 - 19.43	Perf YTD	-24.06%
Dividend	-	P/FCF	11.25	EPS past 5Y	-9.10%	ROI	-26.10%	52W High	-38.03%	Beta	1.73
Dividend %	-	Quick Ratio	4.60	Sales past 5Y	24.50%	Gross Margin	-	52W Low	57.39%	ATR	0.64
Employees	413	Current Ratio	4.60	Sales Q/Q	-53.00%	Oper. Margin	-	RSI (14)	52.65	Volatility	4.26% 5.47%
Optionable	Yes	Debt/Eq	0.00	EPS Q/Q	-830.00%	Profit Margin	-	Rel Volume	0.31	Prev Close	11.85
Shortable	Yes	LT Debt/Eq	0.00	Earnings	Feb 24 AMC	Payout	-	Avg Volume	1.47M	Price	12.04
Recom	2.20	SMA20	2.85%	SMA50	0.03%	SMA200	0.39%	Volume	78,032	Change	1.60%

Jan-07-21

Resumed

Guggenheim

Neutral

$16

Jan-06-21

Initiated

Stifel

Hold

$16

Dec-16-20

Resumed

H.C. Wainwright

Buy

$25

Sep-08-20

Initiated

BofA Securities

Buy

$20

Jul-07-20

Initiated

SunTrust

Buy

$22

Aug-26-19

Initiated

H.C. Wainwright

Buy

$16

Nov-14-18

Downgrade

JP Morgan

Overweight → Neutral

Nov-09-18

Downgrade

Guggenheim

Buy → Neutral

Oct-10-18

Initiated

Guggenheim

Buy

Jun-20-18

Initiated

BofA/Merrill

Buy

$24

Nov-15-17

Upgrade

Piper Jaffray

Neutral → Overweight

Jun-22-17

Resumed

Jefferies

Buy

$17

Nov-01-16

Downgrade

Wedbush

Outperform → Neutral

$30 → $4

Oct-19-16

Downgrade

Piper Jaffray

Overweight → Neutral

Dec-04-15

Initiated

Wells Fargo

Outperform

Oct-23-15

Resumed

Jefferies

Buy

May-03-13

Initiated

BioLogic Equity Research

Sell

Feb-23-11

Reiterated

JMP Securities

Mkt Outperform

$9 → $12

Jul-29-10

Reiterated

Wedbush

Outperform

$12 → $13

Oct-19-09

Initiated

Brean Murray

Sell

Mar-25-21 08:30AM	Sangamo Therapeutics Announces Participation at Guggenheim Healthcare Talks: 2021 Genomic Medicines & Rare Disease Business Wire +6.14%
Mar-17-21 04:30PM	Sangamo Announces EMA Releases Details Supporting Orphan Designation for BIVV003 for the Treatment of Sickle Cell Disease Business Wire
Mar-16-21 03:26PM	Wells Fargo: 2 Compelling Stocks With Over 70% Upside Potential TipRanks
Mar-09-21 05:10AM	What Type Of Shareholders Make Up Sangamo Therapeutics, Inc.'s (NASDAQ:SGMO) Share Registry? Simply Wall St. +5.88%
Mar-01-21 11:10AM	Is Sangamo Therapeutics (SGMO) Stock a Buy For 2021? Insider Monkey
Feb-26-21 09:34AM	Stock Market News for Feb 26, 2021 Zacks
Feb-25-21 06:30PM	Sangamo Therapeutics Inc (SGMO) Q4 2020 Earnings Call Transcript Motley Fool -10.62%
Feb-24-21 04:01PM	Sangamo Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2020 Financial Results Business Wire
03:15PM	Sangamo Therapeutics, Inc. to Host Earnings Call ACCESSWIRE
Feb-18-21 04:15PM	Sangamo Therapeutics Announces Participation at Upcoming Investor Conferences Business Wire
Feb-17-21 04:15PM	Sangamo Therapeutics Announces Fourth Quarter and Full Year 2020 Conference Call and Webcast Business Wire
Feb-01-21 04:05PM	Sangamo Therapeutics Appoints Rob Schott, MD, MPH, FACC, as Head of Development; Elevates Jason Fontenot, PhD to Chief Scientific Officer Business Wire
Jan-07-21 11:25PM	Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Analysts Just Slashed Next Year's Estimates Simply Wall St.
Jan-06-21 04:10PM	Sangamo Therapeutics Announces Departure of Chief Financial Officer Sung Lee Business Wire
Jan-05-21 08:00AM	Sangamo Therapeutics to Present at the 39th Annual J.P. Morgan Healthcare Conference Business Wire
Dec-15-20 10:54AM	Sangamo Therapeutics (SGMO) Catches Eye: Stock Jumps 6.5% Zacks
10:40AM	Sangamo Therapeutics Sees RS Rating Rise To 85 And Composite Rating At 81 Investor's Business Daily
Dec-14-20 08:43AM	Are Options Traders Betting on a Big Move in Sangamo Therapeutics (SGMO) Stock? Zacks +6.51%
Dec-10-20 02:03PM	CRISPR Gene Editing: Owning the Future of Medicine Zacks +52.98%
Dec-07-20 07:00AM	Pfizer and Sangamo Announce Updated Phase 1/2 Results Showing Sustained Factor VIII Activity Levels in 3x1013 VG/KG Cohort Through One Year Following Hemophilia A Gene Therapy Business Wire -7.11%
Nov-30-20 06:42AM	How Much Did Sangamo Therapeutics'(NASDAQ:SGMO) Shareholders Earn From Share Price Movements Over The Last Three Years? Simply Wall St.
Nov-24-20 11:39AM	Pfizer (PFE) Begins Phase III Study on Hemophilia Candidate Zacks
Nov-05-20 08:00AM	Sangamo Therapeutics Announces Participation at Upcoming Investor Conferences Business Wire
Nov-04-20 11:02PM	Sangamo Therapeutics Inc (SGMO) Q3 2020 Earnings Call Transcript Motley Fool +10.99%
05:45PM	Sangamo Therapeutics (SGMO) Reports Q3 Loss, Tops Revenue Estimates Zacks
04:01PM	Sangamo Therapeutics Reports Business Highlights and Third Quarter 2020 Financial Results Business Wire
03:15PM	Sangamo Therapeutics, Inc. to Host Earnings Call ACCESSWIRE
Oct-28-20 04:15PM	Sangamo Therapeutics Announces Third Quarter 2020 Conference Call and Webcast Business Wire
12:32PM	Will Sangamo Therapeutics (SGMO) Report Negative Q3 Earnings? What You Should Know Zacks
Oct-16-20 11:36AM	Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Insiders Increased Their Holdings Simply Wall St.
Oct-07-20 06:45AM	Pfizer and Sangamo Dose First Participant in Phase 3 Study Evaluating Hemophilia A Gene Therapy Treatment Business Wire
Oct-05-20 11:41AM	Is Sangamo Therapeutics, Inc. (SGMO) A Good Stock To Buy? Insider Monkey +5.96%
Sep-28-20 08:30AM	Sangamo Therapeutics Announces Participation at Upcoming Investor Conferences Business Wire
Sep-15-20 10:48AM	Sangamo Therapeutics Scores Relative Strength Rating Upgrade; Hits Key Threshold Investor's Business Daily
Sep-11-20 08:30AM	Sangamo Therapeutics Appoints Kenneth Hillan to Its Board of Directors Business Wire
Sep-10-20 12:11PM	Sangamo Therapeutics Getting Closer To Key Technical Benchmark Investor's Business Daily
Sep-02-20 04:15PM	Sangamo Therapeutics Announces Participation at Upcoming Investor Conferences Business Wire
Sep-01-20 03:47PM	How Much Is Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Paying Its CEO? Simply Wall St. -9.42%
Aug-20-20 09:43AM	BioMarin Stocks Near-Term Growth Is Gone, Analyst Says. Heres Why. Barrons.com
Aug-19-20 12:19PM	BioMarin Stock Slumps After FDAs Surprise Rejection of a Hemophilia Gene Therapy Barrons.com
Aug-10-20 08:30AM	Sangamo Therapeutics to Present at the 2020 Wedbush PacGrow Healthcare Conference Business Wire
Aug-05-20 06:35PM	Sangamo Therapeutics (SGMO) Reports Q2 Loss, Lags Revenue Estimates Zacks
04:01PM	Sangamo Therapeutics Reports Business Highlights and Second Quarter 2020 Financial Results Business Wire
Aug-03-20 12:49PM	Did Hedge Funds Make The Right Call On Sangamo Therapeutics, Inc. (SGMO) ? Insider Monkey +6.56%
Jul-30-20 07:00AM	Sangamo Announces Global Collaboration With Novartis to Develop Genomic Medicines for Autism and Other Neurodevelopmental Disorders Business Wire +14.55%
Jul-29-20 04:15PM	Sangamo Therapeutics Announces Second Quarter 2020 Conference Call and Webcast Business Wire
12:33PM	Sangamo Therapeutics (SGMO) Earnings Expected to Grow: Should You Buy? Zacks
Jul-27-20 06:07PM	4 More Biotechs Break From IPO Starting Gate GuruFocus.com
Jul-09-20 07:43AM	How Many Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Shares Do Institutions Own? Simply Wall St.
07:31AM	3 Top Biotech Stocks to Watch in July Motley Fool
Jun-24-20 08:00AM	Sangamo Announces R&D Organization Changes Business Wire -5.20%
Jun-19-20 12:22PM	Hedge Funds Are Getting Crazy About Sangamo Therapeutics, Inc. (SGMO) Insider Monkey -6.37%
Jun-18-20 09:44AM	Pfizer's hemophilia gene therapy shows sustained effect in early-stage study Reuters -13.18%
09:01AM	Pfizer's hemophilia gene therapy shows sustained effect in early-stage study Reuters
09:00AM	Pfizer and Sangamo Announce Updated Phase 1/2 Results Showing Sustained Factor VIII Activity Levels and No Bleeding Events or Factor Usage in 3e13 vg/kg Cohort Following giroctocogene fitelparvovec (SB-525) Gene Therapy Business Wire
Jun-16-20 08:36AM	Are Options Traders Betting on a Big Move in Sangamo (SGMO) Stock? Zacks
Jun-15-20 10:40PM	Edited Transcript of SGMO.OQ earnings conference call or presentation 11-May-20 9:00pm GMT Thomson Reuters StreetEvents
Jun-14-20 06:00AM	Better Buy: CRISPR Therapeutics vs. Sangamo Therapeutics Motley Fool
Jun-11-20 05:14PM	Sangamo Stock Avoids Biotech Pitfall On Pfizer-Partnered Gene Therapy Investor's Business Daily
May-29-20 09:00AM	Sangamo Therapeutics Announces Participation at the Jefferies Virtual Healthcare Conference Business Wire
May-12-20 09:15AM	Sangamo Therapeutics Announces Participation at the Bank of America 2020 Health Care Conference Business Wire +8.06%
01:01AM	Sangamo Therapeutics Inc (SGMO) Q1 2020 Earnings Call Transcript Motley Fool
May-11-20 05:15PM	Sangamo Therapeutics (SGMO) Reports Q1 Loss, Misses Revenue Estimates Zacks
04:01PM	Sangamo Therapeutics Reports Business Highlights and First Quarter 2020 Financial Results Business Wire
May-07-20 05:15PM	Sangamo Therapeutics Announces Virtual Format for 2020 Annual Meeting Business Wire
May-05-20 11:30AM	Is Sangamo Therapeutics (SGMO) Stock Outpacing Its Medical Peers This Year? Zacks
May-04-20 04:15PM	Sangamo Therapeutics Announces First Quarter 2020 Conference Call and Webcast Business Wire +5.41%
Apr-29-20 07:14AM	Better Buy: Cara Therapeutics vs. Sangamo Therapeutics Motley Fool
Apr-28-20 04:30PM	Sangamo Therapeutics Announces Presentations at 2020 Annual Meeting of the American Society of Gene & Cell Therapy Business Wire
Apr-21-20 07:00AM	Mogrify and Sangamo announce collaboration and exclusive license agreement for Mogrifys iPSC- and ESC-derived regulatory T cells Business Wire
Apr-19-20 08:09AM	How Many Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Shares Did Insiders Buy, In The Last Year? Simply Wall St.
Apr-17-20 08:30AM	Sangamo Appoints D. Mark McClung as Executive Vice President and Chief Business Officer Business Wire
Apr-09-20 08:00AM	Sangamo Announces Closing of Biogen Collaboration Agreement Business Wire +6.88%
Mar-09-20 01:37PM	Sangamo Therapeutics Shows Promise TheStreet.com -11.15%
Mar-06-20 05:39AM	Will Sangamo Therapeutics Continue to Surge Higher? Zacks
Mar-05-20 08:27AM	Top Ranked Momentum Stocks to Buy for March 5th Zacks
Mar-04-20 09:55AM	Biotech Stock Roundup: GILD to Buy Forty Seven, Pipeline Updates From BIIB & More Zacks
Mar-02-20 08:30AM	Sangamo Therapeutics Announces Participation at Upcoming Investor Conferences Business Wire
Feb-28-20 04:48PM	What A Biogen Deal Means For This Small Genetic Medicines Outlet Investor's Business Daily +27.98%
11:08AM	Sangamo Stock Is Soaring on Plan to Collaborate With Biogen Barrons.com
08:15AM	Sangamo Therapeutics (SGMO) Surpasses Q4 Earnings and Revenue Estimates Zacks
07:00AM	Sangamo Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results Business Wire
06:34AM	Biogen pays California biotech $350M upfront for Alzheimer's gene therapy American City Business Journals
Feb-27-20 04:06PM	Biogen and Sangamo Announce Global Collaboration to Develop Gene Regulation Therapies for Alzheimers, Parkinsons, Neuromuscular, and Other Neurological Diseases GlobeNewswire
Feb-25-20 04:30PM	Sangamo Therapeutics Announces Fourth Quarter and Full Year 2019 Conference Call and Webcast Business Wire
Feb-20-20 12:31PM	Earnings Preview: Sangamo Therapeutics (SGMO) Q4 Earnings Expected to Decline Zacks
Feb-12-20 08:00AM	Sangamo Therapeutics Appoints John Markels to Its Board of Directors Business Wire
Feb-04-20 05:29PM	Goldman Sachs Sets BioMarin Target 75% Above Current Price GuruFocus.com
Jan-20-20 12:07PM	Is Sangamo Therapeutics's (NASDAQ:SGMO) Share Price Gain Of 129% Well Earned? Simply Wall St.
Jan-16-20 10:34AM	Big Pharma Remains Accused of Keeping Prices High. That Wont Change Soon. Barrons.com
Jan-13-20 05:00AM	Top Picks 2020- Sangamo Therapeutics SGMO MoneyShow
Jan-09-20 08:30AM	Sangamo Therapeutics to Present at the 38th Annual J.P. Morgan Healthcare Conference Business Wire
Dec-30-19 03:40PM	Axsome Therapeutics jumps as migraine drug hits goals in late-stage trial Yahoo Finance Video
Dec-24-19 09:30AM	BioMarin Files BLA for Gene Therapy to Treat Hemophilia A Zacks
Dec-23-19 06:50AM	Sangamo Announces Early Completion of Transfer to Pfizer of SB-525 Hemophilia A Gene Therapy IND and an Earned $25 Million Milestone Payment Business Wire +6.36%
Dec-17-19 06:45AM	Sangamo Highlights Advancements in Genomic Medicine Pipeline and Expanded R&D and Manufacturing Capabilities at R&D Day Business Wire
Dec-12-19 07:37PM	Hedge Funds Are Dumping Sangamo Therapeutics, Inc. (SGMO) Insider Monkey
Dec-09-19 06:45AM	Sangamo Announces Preliminary Results From the First Three Patients in a Phase 1/2 Study Evaluating ST-400 Ex Vivo Gene-edited Cell Therapy in Beta Thalassemia Business Wire -11.58%
Dec-07-19 09:00AM	Sangamo and Pfizer Announce Updated Phase 1/2 Results Showing Sustained Increased Factor VIII Activity Through 44 Weeks Following SB-525 Gene Therapy Treatment Business Wire
Dec-06-19 09:33AM	The Zacks Analyst Blog Highlights: uniQure, Sarepta Therapeutics, BioMarin Pharmaceutical and Sangamo Therapeutics Zacks

Sangamo Therapeutics, Inc., a clinical-stage biotechnology company, focuses on translating science into genomic medicines that transform patients' lives using platform technologies in gene therapy, cell therapy, genome editing, and genome regulation. The company offers zinc finger protein (ZFP), a technology platform for making zinc finger nucleases, which are proteins used in modifying DNA sequences by adding or knocking out specific genes or genome editing; and ZFP transcription factors proteins used in increasing or decreasing gene expression. It develops SB-525, which is in Phase III AFFINE clinical trial for the treatment of hemophilia A; ST-920, a gene therapy, which is in Phase I/II STAAR clinical trials for the treatment of Fabry disease; BIVV003, a cell therapy, which is in Phase I/II PRECIZN-1 clinical trials for the treatment of sickle cell disease; ST-400, a cell therapy, which is in Phase I/II Thales clinical trials for the treatment of transfusion dependent beta thalassemia. The company also develops TX200, chimeric antigen receptor for the treatment of HLA-A2 mismatched kidney transplant rejection; KITE-037, an anti-CD19 CAR-T cell therapy for the treatment of cancer. ST-101 gene therapy for phenylketonuria. It has collaborative and strategic partnerships with Biogen MA, Inc.; Kite Pharma, Inc.; Pfizer Inc.; Sanofi Genzyme; Shire International GmbH; Dow AgroSciences LLC; Sigma-Aldrich Corporation; Genentech, Inc.; Open Monoclonal Technology, Inc.; F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; and California Institute for Regenerative Medicine. The company was formerly known as Sangamo BioSciences, Inc. and changed its name to Sangamo Therapeutics, Inc. in January 2017. Sangamo Therapeutics, Inc. was founded in 1995 and is headquartered in Brisbane, California.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
LOEB GARY	EVP, General Counsel & Sec.	Mar 23	Option Exercise	11.02	11,981	132,031	100,762	Mar 25 07:19 PM
LOEB GARY	EVP, General Counsel & Sec.	Mar 23	Sale	13.13	17,524	230,042	83,238	Mar 25 07:19 PM
Ramelmeier Rolf Andrew	EVP, Technical Operations	Dec 31	Sale	16.74	2,464	41,247	65,978	Jan 06 04:27 PM
Ramelmeier Rolf Andrew	EVP, Technical Operations	Dec 24	Sale	18.13	3,331	60,391	68,442	Dec 30 07:51 PM
Ramasastry Saira	Director	Dec 17	Option Exercise	5.99	10,000	59,900	25,000	Dec 18 07:18 PM
Ramasastry Saira	Director	Dec 17	Sale	13.27	10,000	132,747	15,000	Dec 18 07:18 PM

open in yahoo | open in reuters | open in marketwatch | open in google

Upgrade your FINVIZ experience